title: Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure.
abstract: Hurler's syndrome (HS), the most severe form of mucopolysaccharidosis type-I, causes progressive deterioration of the central nervous system and death in childhood. Allogeneic stem cell transplantation (SCT) before the age of 2 years halts disease progression. Graft failure limits the success of SCT. We analyzed data on HS patients transplanted in Europe to identify the risk factors for graft failure. We compared outcomes in 146 HS patients transplanted with various conditioning regimens and grafts. Patients were transplanted between 1994 and 2004 and registered to the European Blood and Marrow Transplantation database. Risk factor analysis was performed using logistic regression. 'Survival' and 'alive and engrafted'-rate after first SCT was 85 and 56%, respectively. In multivariable analysis, T-cell depletion (odds ratio (OR) 0.18; 95% confidence interval (CI) 0.04-0.71; P=0.02) and reduced-intensity conditioning (OR 0.08; 95% CI 0.02-0.39; P=0.002) were the risk factors for graft failure. Busulfan targeting protected against graft failure (OR 5.76; 95% CI 1.20-27.54; P=0.028). No difference was noted between cell sources used (bone marrow, peripheral blood stem cells or cord blood (CB)); however, significantly more patients who received CB transplants had full-donor chimerism (OR 9.31; 95% CI 1.06-82.03; P=0.044). These outcomes may impact the safety/efficacy of SCT for 'inborn-errors of metabolism' at large. CB increased the likelihood of sustained engraftment associated with normal enzyme levels and could therefore be considered as a preferential cell source in SCT for 'inborn errors of metabolism'.
authors.affiliation: Department of Immunology/BMT, Wilhelmina Children's Hospital, Utrecht Medical Center, Utrecht, The Netherlands. J.J.Boelens@umcutrecht.nl
authors.forename: J J
authors.initials: JJ
authors.lastname: Boelens
authors.forename: R F
authors.initials: RF
authors.lastname: Wynn
authors.forename: A
authors.initials: A
authors.lastname: O'Meara
authors.forename: P
authors.initials: P
authors.lastname: Veys
authors.forename: Y
authors.initials: Y
authors.lastname: Bertrand
authors.forename: G
authors.initials: G
authors.lastname: Souillet
authors.forename: J E
authors.initials: JE
authors.lastname: Wraith
authors.forename: A
authors.initials: A
authors.lastname: Fischer
authors.forename: M
authors.initials: M
authors.lastname: Cavazzana-Calvo
authors.forename: K W
authors.initials: KW
authors.lastname: Sykora
authors.forename: P
authors.initials: P
authors.lastname: Sedlacek
authors.forename: A
authors.initials: A
authors.lastname: Rovelli
authors.forename: C S P M
authors.initials: CS
authors.lastname: Uiterwaal
authors.forename: N
authors.initials: N
authors.lastname: Wulffraat
mesh_terms: D002066:Busulfan / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D016208:Databases, Factual; D018572:Disease-Free Survival; D005060:Europe; D005260:Female; D006084:Graft Rejection / Q000209:etiology / Q000401:mortality*; D006085:Graft Survival / Q000187:drug effects; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016015:Logistic Models; D008212:Lymphocyte Depletion / Q000009:adverse effects; D008297:Male; D008059:Mucopolysaccharidosis I / Q000401:mortality* / Q000628:therapy; D019653:Myeloablative Agonists / Q000008:administration & dosage; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous
chemical_list: D019653:Myeloablative Agonists; D002066:Busulfan